89
The positron emission tomography (PET) radioisotope zirconium-89 (89 Zr) is particularly suited for antibody imaging, ... 25 µg and 100 µg for each tracer. PET quantification showed [89 Zr] ...
89Zr Radiochemistry for PET
II. 89 Zr Physics. 89 Zr is a neutron deficient isotope of Zirconium with 49 neutrons and 40 protons, and it decays with a half-life of 3.27 days to 89 Y. The decay proceeds via electron capture (77%), and positron emission (23%). Both modes of decay lead primarily (99%) to a 9/2+ state in 89 Y, which de-excites through M4 emission of a 909 keV gamma ray to …
First-in-human immunoPET imaging of HIV-1 infection using 89 …
The objectives of the study are to determine the dosimetry and whole body distribution of the novel PET tracer, 89 Zr-VRC01, ... Zirconium-89 (half-life = 78.4 h, 23% positron emission) was then ...
Molecular Imaging of a Zirconium-89 Labeled Antibody …
We herein demonstrate the zirconium-89 (Zr-89) conjugation and radiolabeling of IIIB6 in vitro and in vivo ... Representative maximum intensity projections (MIP) of a athymic nude mouse injected with 10.1 MBq [89 Zr]IIIB6. Following tracer injection, microPET/CT images were acquisited for 20 min at a 2 h, b 4 h, c 6 h and d 24 …
The Radiopharmaceutical Chemistry of Zirconium-89
Zirconium-89 is a residualizing, positron-emitting radionuclide whose physical half-life provides an excellent match for the pharmacokinetic profiles of many antibodies. …
Whole-body CD8 + T cell visualization before and …
We assessed safety, imaging dose and timing, pharmacokinetics and immunogenicity of zirconium-89-labeled, CD8-specific, one-armed antibody positron emission tomography tracer …
(PDF) PET tracers based on Zirconium-89
This review article will. summarize the current status of PET tracers based on 89 Zr. Zirconium is a transition metal in Group IVB of the periodic table. 89 Zr, which decays by. positron emission ...
Radiation Dosimetry Study of [(89)Zr]rituximab Tracer for …
Purpose: We evaluated the dosimetry of [(89)Zr]rituximab, an anti-CD20 immunoPET tracer to image B cell non-Hodgkin's lymphoma (NHL) using a humanized transgenic mouse model that expresses human CD20 transgenic mice (huCD20TM). Procedures: Rituximab was conjugated to desferrioxamine (Df) for radiolabeling of Zirconium-89. …
Development of 89Zr-anti-CD103 PET imaging for non …
The PET isotope zirconium-89 (89 Zr; t 1/2 =78.4 hours) is favorable for radiolabeling mAbs, as its physical half-life matches the time mAbs require for optimal target-to-background signals.47 Recently, a first-in-human PET imaging study with 89 Zr-labeled atezolizumab (anti-PD-L1) showed that tracer uptake appeared to be a predictor of ...
89 Zr-PET imaging in humans: a systematic review
Here, we aimed to develop an improved zirconium-89-labeled GLP-1RA with increased molar activity to increase the uptake in low receptor density tissues, such …
Conjugation and radiolabeling of monoclonal antibodies with zirconium …
The positron emitter zirconium-89 (89Zr) has very attractive properties for positron emission tomography (PET) imaging of intact monoclonal antibodies (mAbs) using immuno-PET. ... Trace metal ions ...
Production, applications and status of zirconium-89
Zirconium-89 has attracted huge interests and is used in tracing and quantification of slow biological processes and labeling of long half-live biomolecules such as monoclonal antibodies for pharmacokinetic studies and clinical trials. In this review, a concise introduction to targetry, irradiation data, separation and coordination chemistry …
Zirconium-89 labeled antibodies: a new tool for molecular …
A direct comparison between 89 Zr-bevacizumab and an irrelevant 89 Zr-labeled IgG revealed a significantly higher tumor uptake of 89 Zr-bevacizumab in nude mice with human ovarian SK-OV-3 tumors . Besides using 89 Zr-bevacizumab as PET tracer for noninvasive in vivo imaging of VEGF expression in the tumor microenvironment, …
Frontiers | Immuno-Positron Emission Tomography with Zirconium-89 …
Molecular imaging with positron emission tomography (PET) using zirconium-89 (89 Zr) ... This causes an "antigen sink" that absorbs the tracer dose, leaving insufficient 89 Zr-mAb to target all tumor lesions. Therefore, for each mAb, information should be obtained to assess whether a dose-dependent correlation between imaging …
First-in-Human Imaging of 89Zr-oxine Labelled Autologous …
Zirconium-89 is a β+-emitting radiometal with a relatively long physical half-life (t ½ = 3.27 days) that matches the biological half-life of antibodies and intact cells, allowing imaging at later time points not possible with …
Current Perspectives on 89Zr-PET Imaging
89 Zr is an emerging radionuclide that plays an essential role in immuno-positron emission tomography (PET) imaging. The long half-life of 89 Zr (t 1/2 = 3.3 days) is favorable for evaluating the in vivo distribution of monoclonal antibodies. Thus, the use of 89 Zr is promising for monitoring antibody-based cancer therapies. Immuno-PET combines …
89 Zr as a promising radionuclide and it's applications for …
Molecular imaging is based on two important concepts of the "Tracer Principle" and the "Magic Bullet", which were developed respectively by George de Hevey and Paul Ehrlich. ... (64 Cu) and zirconium-89 (89 Zr) . Zirconium-89 (89 Zr) Early studies about 89 Zr and its radiochemistry were reported (in the 1960 s) by the National …
New Long-Acting [ 89 Zr]Zr-DFO GLP-1 PET Tracers with …
Positron emission tomography (PET) imaging is used in drug development to noninvasively measure biodistribution and receptor occupancy. Ideally, PET tracers retain target binding and biodistribution properties of the investigated drug. Previously, we developed a zirconium-89 PET tracer based on a long-circulating glucagon-like peptide …
Abstract
Immuno-PET detection of LAG-3 expressing intratumoral lymphocytes using the zirconium-89 radiolabeled fully human anti-LAG-3 antibody REGN3767 [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 …
First-in-human immunoPET imaging of HIV-1 infection using …
The prior primate SIV immunoPET study demonstrated increased tracer uptake in nasopharyngeal associated lymphoid tissue (NALT) 6, and we also observed …
Zirconium 89
11 C-docetaxel has been studied in lung cancer patients, and the uptake of the tracer was predictive of response measured on subsequent CT. 142 Monoclonal antibodies such as bevacizumab can also be labeled using zirconium-89, which has a half-life of 78 hours with kinetics matching those of monoclonal antibodies.
89Zr-immuno-PET using the anti-LAG-3 tracer [89Zr]Zr-BI …
Purpose: Although lymphocyte activation gene-3 (LAG-3) directed therapies demonstrate promising clinical anti-cancer activity, only a subset of patients seems to benefit and predictive biomarkers are lacking. Here, we explored the potential use of the anti-LAG-3 antibody tracer [89 Zr]Zr-BI 754111 as a predictive imaging biomarker and …
Zirconium-89 radio-nanochemistry and its applications towards …
Zirconium-89 half-life of ca. 3.3 days matches the pharmacokinetics of antibodies (half-life of 3–4 days), thus rendering a more suitable isotope for antibody-based immuno-PET imaging with respect to other metallic radioisotopes such as copper-64 or yttrium-86 [4].An additional reason why zirconium-89 has been deemed in the past …
Zirconium-89 Labeled Antibodies: A New Tool for Molecular …
A direct comparison between 89 Zr-bevacizumab and an irrelevant 89 Zr-labeled IgG revealed a significantly higher tumor uptake of 89 Zr-bevacizumab in nude mice with human ovarian SK-OV-3 tumors . Besides using 89 Zr-bevacizumab as PET tracer for noninvasive in vivo imaging of VEGF expression in the tumor microenvironment, …
Zirconium-89 Labeled Antibodies: A New Tool for Molecular
A direct comparison between 89 Zr-bevacizumab and an irrelevant 89 Zr-labeled IgG revealed a significantly higher tumor uptake of 89 Zr-bevacizumab in nude mice with human ovarian SK-OV-3 tumors . Besides using 89 Zr-bevacizumab as PET tracer for noninvasive in vivo imaging of VEGF expression in the tumor microenvironment, potentially it can ...
Immuno-Positron Emission Tomography with Zirconium-89 …
This causes an "antigen sink" that absorbs the tracer dose, leaving insufficient 89 Zr-mAb to target all tumor lesions. Therefore, for each mAb, information should be obtained to assess whether a dose-dependent correlation between imaging dose and tumor uptake exists. ... Performance of immuno-positron emission tomography with …
Zirconium-89 Labeled Antibodies: A New Tool for …
The production of 89Zr, the bioconjugation strategies, and applications in (pre-)clinical studies of 89Zr-based immuno-PET in oncology will be discussed, and the ongoing development of new 89ZR-labeled antibodies directed against novel tumor targets is expected to expand applications in the medical imaging. Antibody based positron …
Construction and preclinical evaluation of a zirconium-89 …
Objectives: The aim of this study was to design a novel tracer targeting programmed cell death-ligand 2 (PD-L2) to dynamically monitor PD-L2 expression and perform preclinical screening to identify patients who may benefit from immune checkpoint inhibitor therapy (ICI) therapy. Methods: 89 Zr labelling of DFO-conjugated PD-L2 antibody (ATL2) was …
Aplagon Joins The TRACER Excellence Program to Perform …
The study will be executed in collaboration with TRACER B.V. ("TRACER"), a CRO specializing in molecular imaging techniques and fast in-human clinical trials. The project is performed under The TRACER Excellence Program (TEP). The study will be based on APAC that is coupled to zirconium-89 without altering the functionalities of …
Construction and preclinical evaluation of a zirconium-89 …
A zirconium-89 labelled antibody, [89 Zr]Zr-DFO-ATL2, was developed for the PET imaging of PD-L2. The tracer was generated at high radiochemical yield with high …